# Development of S-PCT3010 to treat cognitive impairment in Alzheimers Disease

> **NIH NIH R44** · POLYCORE THERAPEUTICS, LLC · 2021 · $456,633

## Abstract

PolyCore Therapeutics LLC is developing S-PCT3010 as a therapeutic for improved cognitive
function in patients suffering from Parkinson’s Disease and is proposing to evaluate S-PCT3010
as a therapeutic for improved cognitive function in Alzheimer’s patients. S-PCT3010 is a
selective D3R agonist with biased signaling through the G-protein pathway which does not
recruit -arrestin. The drug does not induce tolerance in vitro or in vivo in rats. Further, S-
PCT3010 is a selective inhibitor of norepinephrine transporter and promotes improvement in
sustaining attention and cognitive flexibility in rodent models of Parkinson’s Disease without
producing compulsive or impulsive behaviors. S-PCT3010 is highly pharmaceutically tractable
with excellent oral bioavailability and blood brain barrier penetration. In this proposal, PolyCore
Therapeutics LLC is proposing to complete pilot studies in a in vivo transgenic mouse model of
Alzheimer’s Disease evaluating both behavioral and pathological changes following S-PCT3010
administration.
 Per the Alzheimer’s Association, an estimated 5.8 million Americans age 65 and older
are living with Alzheimer's dementia in 2020 with eighty percent over 75 years old. These
numbers represent one in ten people over the age of 65 living with various cognitive
impairments. Alzheimer's Disease also represents a significant risk of death and is the sixth-
leading cause of death in the United States. The financial burden of Alzheimer's Disease is
projected to cost more than $1.1 trillion dollars in 2020, and a significant portion of this cost
relates to patient management around cognitive disorders and dementia. In this application,
PolyCore Therapeutics LLC teams with leading Parkinson’s and Alzheimer’s researchers at
Drexel University to evaluate the changes in cognitive function resulting from Alzheimer’s
Disease. The team plans to evaluate S-PCT3010 for use in mitigation of cognitive disorders
and memory loss using a transgenic mouse model of Alzheimer’s disease. PolyCore
Therapeutics LLC is actively developing S-PCT3010 for Parkinson Disease under an ongoing
Phase II SBIR (1R44NS117201-01).

## Key facts

- **NIH application ID:** 10287800
- **Project number:** 3R44NS117201-01S1
- **Recipient organization:** POLYCORE THERAPEUTICS, LLC
- **Principal Investigator:** Thais Sielecki
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $456,633
- **Award type:** 3
- **Project period:** 2021-03-01 → 2022-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10287800

## Citation

> US National Institutes of Health, RePORTER application 10287800, Development of S-PCT3010 to treat cognitive impairment in Alzheimers Disease (3R44NS117201-01S1). Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/grant/nih/10287800. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*